Keyphrases
Schizophrenia
100%
Benzoate
100%
Randomized Placebo-controlled Trial
100%
Add-on Treatment
100%
D-amino Acid Oxidase Activator
100%
Negative Syndrome
75%
Sodium Benzoate
75%
Adverse Effects
50%
N-methyl-D-aspartate Receptor (NMDAR)
50%
Neurocognition
50%
Chronic Schizophrenia
50%
Positive Symptoms
25%
Negative Symptoms
25%
Metabolism
25%
Clinical Efficacy
25%
Quality of Life Scale
25%
Mental Health Care
25%
Placebo
25%
Negative Cognitions
25%
Hyperactivity
25%
Cognitive Function
25%
Receptor-mediated
25%
Antipsychotics
25%
Treatment Research
25%
Global Assessment
25%
Symptom Domains
25%
Processing Speed
25%
Medical Center
25%
Neurotransmission
25%
Enhancing Agents
25%
National Institute of Mental Health
25%
Taiwan
25%
D-amino Acids
25%
Visual Learning
25%
Clinical Global Impression
25%
Pathophysiology of Schizophrenia
25%
Adjunctive Therapy
25%
Hypofunction
25%
Major Medical
25%
New Drug Development
25%
Scale for the Assessment of Negative Symptoms
25%
Mental Health Measurement
25%
Global Improvement
25%
D-amino Acid Oxidase
25%
Novel Treatments
25%
Improved A
25%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Amino Acid Oxidase
100%
Oxidoreductase Inhibitor
100%
Benzoic Acid
100%
Negative Syndrome
71%
Positive Syndrome
57%
Adverse Event
28%
Receptor
28%
N Methyl Dextro Aspartic Acid
28%
Aspartic Acid
28%
Schizophrenia
28%
Drug Development
14%
Antipsychotic
14%
Hyperactivity
14%
Amino Acid
14%
Dopamine Receptor Stimulating Agent
14%
Symptom
14%
Pathophysiology
14%
Isoprenaline
14%